Rajwanth Veluswamy
Co-Director · KRAS-X
Credentials: · · · ·
History
Research
The global burden of lung cancer: current status and future trends
Nature Reviews Clinical Oncology · 2023 · 1,197 citations
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Cell · 2020 · 664 citations
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
Nature · 2024 · 162 citations
18 papers
5 papers
4 papers
4 papers
4 papers
3 papers
3 papers
2 papers
Clinical trials
- 2020–2023
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Principal investigator · Completed · Phase 1, Phase 2
Icahn School of Medicine at Mount Sinai
- 2026–2028
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2
Verastem, Inc.